Physician profile
Christopher E Fundakowski
NPI 1588836126
$9,830.48
in general payments reported to CMS, 2019-2025
9 companies · $5,366 in 2025
The $5,366 reported for 2025 was more than what 96% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $3,525 · 2022: $235 · 2023: $373 · 2024: $207 · 2025: $5,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,220 · Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,220.00 |
| Food and Beverage | $725.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,334.23 | 2025 | Libtayo |
| Intuitive Surgical, INC. | $3,525.15 | 2021 | |
| Optinose US, INC. | $261.38 | 2022-2023 | |
| Stryker Corporation | $173.69 | 2023 | Scopis Ent |
| Acera Surgical, INC. | $162.92 | 2022-2024 | Restrata Wound Matrix |
| Smith+Nephew, INC. | $128.07 | 2024 | Oasis, Stravix Pl |
| Baxter Healthcare | $125.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $83.79 | 2024-2025 | Libtayo |
| Kerecis Limited | $35.96 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fundakowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.